SOLICITATION NOTICE
B -- HUMAN HLA-DP TRANSGENIC MOUSE MODEL OF CHRONIC BERYLLIUM DISEASE AND EVALUATION OF THE RELATIVE CONTRIBUTIONS OF DERMAL AND PULMONARY EXPOSURES IN THE MODEL
- Notice Date
- 7/9/2009
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Acquisition and Assistance Field Branch (Morgantown), 1095 Willowdale Road, Morgantown, West Virginia, 26505
- ZIP Code
- 26505
- Solicitation Number
- 2009-Q-11384
- Archive Date
- 8/8/2009
- Point of Contact
- Kimberly P Groves, Phone: 304-285-5885, Rebecca S Mullenax, Phone: 304-285-5880
- E-Mail Address
-
kpg0@cdc.gov, rmullenax@cdc.gov
(kpg0@cdc.gov, rmullenax@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- NOTICE OF INTENT TO ISSUE A PURCHASE ORDER. The Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (NIOSH), Division of Respiratory Disease Studies (DRDS), Morgantown, WV, hereby announces its intent to issue a purchase order to New York University School of Medicine, for research on "Validation of a Human HLA_DP Transgenic Mouse Model of chronic Beryllium Disease and Evaluation of the Relative Contributions of Dermal and Pulmonary Exposers in the Model". The purpose is as follows: This research seeks to provide data concerning the relative contribution of dermal versus the pulmonary routes of exposure to the development of chronic beryllium disease in the transgenic mouse "knock-in" model that expresses the human HLA-DPB1 gene family, namely: HLA-DPB1*0201, HLA-DPB1*0401 and HLA-DPB1*1701. In addition, this contract will implement the design for experiments to validate the HLA-DPB1 transgenic mouse model experimental design developed for the modified FY07 contract (212-2007-M-20091). The project investigates the hypotheses that: 1. The human HLA-DPB1 gene family influences susceptibility to CBD with HLA-DPB1*1701 > HLA-DPB1*0201 > HLA-DPB1*0401. 2. Dermal exposure to beryllium may cause beryllium sensitization so that low doses of lung-deposited beryllium cause chronic beryllium disease (CBD). Investigation of the first hypothesis is intended validate a transgenic mouse model for CBD and the experimental design for investigating the first hypothesis developed as the result of a previous award (212-2007-M-20091). Investigation of the second hypothesis is intended to determine the relative contributions of dermal versus pulmonary exposures in the human HLA-DP transgenic mouse model of CBD. The outcome of the experiments will be measured by histopathological examination of the lung for a granulomatous response similar to that seen in CBD in humans (Frieman and Hardy, Human Pathology 1:25-44, 1970). These outcomes will be determined by PPRB scientists in HELD/NIOSH. This purchase is supported by justification for other than full and open competition to New York University School of Medicine under authority of 41 U.S.C.253(c)(1). Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 15 days from the posting date of this notice, their written capabilities statement and pricing information in the format they choose, not to exceed 10 pages. Please forward the capability statement and pricing information to Kimberly P. Groves, 2009-Q-11384, CDC NIOSH 1095 Willowdale Road, Morgantown, WV. All vendors must be registered in the Central Contractor Registry (CCR) prior to an award of a federal contract. The website is: www.ccr.gov. The Government will review any/all capabilities statements and pricing information submitted and determine if other qualified sources do exist that could provide this requirement. Information received in response to this announcement will be used solely for the purpose of determining whether to conduct a competitive procurement. If no affirmative responses are received within 15 days, in accordance with FAR 13.106-1(b)(1), negotiations will be conducted with New York University School of Medicine as the only source and a purchase order will be issued without any additional notices being posted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/MNIOSH/2009-Q-11384/listing.html)
- Record
- SN01870316-W 20090711/090710000024-fb29fb2d13fbd0e0cb46e463d576c544 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |